News & insights
Updates on our capabilities, case studies from our programmes, and perspectives on protein and antibody expression, cell-line development and scalable bioprocess.
-
ImmunovaTx achieves >8 g/L titres in its high-expression CHO platform
Through targeted media and feed optimisation and process intensification across the upstream workflow, ImmunovaTx has pushed fed-batch monoclonal antibody titres beyond 8 g/L while maintaining clone stability across more than 60 generations — improving the economics of clinical and commercial supply for partner programmes.
Read more → -
Case study: stable pool delivers GMP-representative material in 6 weeks
For a partner advancing a bispecific antibody, a transposon-based stable pool produced gram-scale, GMP-representative material in six weeks — weeks ahead of the conventional clonal route — enabling tox and developability studies to start while the final clonal line was being locked down.
Read more → -
ImmunovaTx expands single-cell cloning and clonality-assurance capacity
New imaging-based single-cell cloning and analytical capacity strengthen our monoclonality evidence package and shorten the path to a documented, regulatory-ready clonal line — adding capacity and redundancy for partner cell-line development programmes.
Read more →
Media & partnership enquiries
For press, partnership, or scientific enquiries, please get in touch.